Abbott Laboratories (ABT), 2024 Q4 earnings digest

from Earnings Report Digest · host ValueVerge

$ABT just released its Q4 2024 earnings, showcasing a strong quarter with 10% sales growth and 13% EPS growth. Highlights include strong cash flow of $8.5 billion and robust performance across all segments, particularly Diabetes Care +23% growth. For 2025, Abbott forecasts a solid 7.5-8.5% organic sales growth and adjusted EPS in the range of $5.05 to $5.25, indicating double-digit growth potential. However, risks linger regarding foreign exchange impacts and tax rates.

Episode metadata supplied by the publisher feed · Published Jan 23, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Abbott Laboratories (ABT), 2024 Q4 earnings digest

0:00 1:39

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 1 minute long.

When was this Earnings Report Digest episode published?

This episode was published on January 23, 2025.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!